76
|
Manek E, Berke B, Miklosi N, Sajban M, Doman A, Fukuda T, Czakkel O, Laszlo K. Thermal sensitivity of carbon nanotube and graphene oxide containing responsive hydrogels. EXPRESS POLYM LETT 2016. [DOI: 10.3144/expresspolymlett.2016.64] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
77
|
Kuno I, Hashiguchi Y, Kasai M, Fukuda T, Ichimura T, Yasui T, Sumi T. Krukenberg tumor in a 18-year-old-female: a rare case. EUR J GYNAECOL ONCOL 2016; 37:139-141. [PMID: 27048128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
BACKGROUND Krukenberg tumors mostly occur after 40 years. Metastatic ovarian tumors in young age are very rare. CASE A 18-year-old female presented with colon cancer which was accompanied by Krukenberg tumor. The present case was a very rare case of metastatic ovarian tumor in very young age. The present patient presented with abdominal pain. On examination, colon tumor was detected and bilateral ovary were almost normal with only slight swelling. During the operation for colon tumor, biopsy of bilateral ovary was performed for histopathological evaluation. Although there were no specific findings in bilateral ovary, microscopic examination revealed poorly differentiated adenocarcinoma, diffusely invading the ovarian parenchyma. Diagnosis of colon cancer was made postoperatively and ovarian Krukenberg tumor was confirmed. CONCLUSION In case of suspecting colon cancer even in very young patient with normal ovary, biopsy of ovary should be considered for the diagnosis of Krukenberg tumor.
Collapse
|
78
|
Kuno I, Matsumoto Y, Kasai M, Fukuda T, Hashiguchi Y, Ichimura T, Yasui T, Sumi T. Primary mediastinal choriocarcinoma with brain metastasis in a female patient. EUR J GYNAECOL ONCOL 2016; 37:265-266. [PMID: 27172760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
Nongestational choriocarcinoma is very rare and carries a poor prognosis in female patients. In this report, the authors present a case of nongestational choriocarcinoma with brain metastasis in a female. A 58-year-old female with intermittent back pain was referred to a private hospital. On examination, a mediastinal tumor and a pancreatic tumor were detected. Endoscopic ultrasound-guided fine needle aspiration biopsy of the tumor was performed for histological evaluation. Pathological diagnosis was difficult because only a small amount of tissue was collected. Head MRI showed multiple metastatic tumors in the brain. The patient was diagnosed with primary mediastinal choriocarcinoma with brain metastasis. She was treated with one course of an etoposide, methotrexate, dactinomycin, cyclophosphamide, and vincristine regimen, but her general condition gradually deteriorated, and she died on day 41. Nongestational choriocarcinoma is drug resistant, whereas gestational choriocarcinoma has better chemotherapeutic sensitivity.
Collapse
|
79
|
Inoue Y, Fuji S, Tanosaki R, Fukuda T. Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality. Bone Marrow Transplant 2015; 51:725-7. [DOI: 10.1038/bmt.2015.315] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
80
|
Yanai S, Hashiguchi Y, Kasai M, Fukuda T, Ichimura T, Yasui T, Sumi T. Early operative treatment of anti-N-methyl D-aspartate (anti-NMDA) receptor encephalitis in a patient with ovarian teratoma. CLIN EXP OBSTET GYN 2015. [DOI: 10.12891/ceog1999.2015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
81
|
Fuji S, Fujiwara H, Nakano N, Wake A, Inoue Y, Fukuda T, Hidaka M, Moriuchi Y, Miyamoto T, Uike N, Taguchi J, Eto T, Tomoyose T, Kondo T, Yamanoha A, Ichinohe T, Atsuta Y, Utsunomiya A. Early application of related SCT might improve clinical outcome in adult T-cell leukemia/lymphoma. Bone Marrow Transplant 2015; 51:205-11. [PMID: 26524263 DOI: 10.1038/bmt.2015.265] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2015] [Revised: 08/31/2015] [Accepted: 09/14/2015] [Indexed: 02/08/2023]
Abstract
Allogeneic hematopoietic SCT (allo-HSCT) is a curative treatment for aggressive adult T-cell leukemia/lymphoma (ATLL). Considering the dismal prognosis associated with conventional chemotherapies, early application of allo-HSCT might be beneficial for patients with ATLL. However, no previous study has addressed the optimal timing of allo-HSCT from related donors. Hence, to evaluate the impact of timing of allo-HSCT for patients with ATLL, we retrospectively analyzed data from patients with ATLL who received an allo-HSCT from a related donor. The median age was 52 years. Patients were grouped according to the interval from diagnosis to allo-HSCT: early transplant group, <100 days, n=72; late transplant group, ⩾100 days, n=428. The corresponding constituents of disease status were not statistically different between the two groups (P=0.11). The probability of OS in the early transplant group was significantly higher than that in the late transplant group (4-year OS, 49.3% vs 31.2%). Multivariate analysis revealed that late allo-HSCT was an unfavorable prognostic factor for OS (hazard ratio, 1.46; 95% confidence interval (CI), 1.01-2.11; P=0.04). Despite the limitations of a retrospective study, it might be acceptable to consider early application of allo-HSCT for ATLL.
Collapse
|
82
|
Wakita S, Yamaguchi H, Ueki T, Usuki K, Kurosawa S, Kobayashi Y, Kawata E, Tajika K, Gomi S, Koizumi M, Fujiwara Y, Yui S, Fukunaga K, Ryotokuji T, Hirakawa T, Arai K, Kitano T, Kosaka F, Tamai H, Nakayama K, Fukuda T, Inokuchi K. Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia. Leukemia 2015; 30:545-54. [DOI: 10.1038/leu.2015.288] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2015] [Revised: 10/04/2015] [Accepted: 10/07/2015] [Indexed: 01/07/2023]
|
83
|
Tanaka U, Sanui T, Fukuda T, Toyoda K, Taketomi T, Atomura R, Yamamichi K, Maeda H, Nishimura F. Sprouty2 inhibition promotes proliferation and migration of periodontal ligament cells. Oral Dis 2015; 21:977-86. [DOI: 10.1111/odi.12369] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2015] [Revised: 08/16/2015] [Accepted: 08/26/2015] [Indexed: 11/30/2022]
|
84
|
Agafonova N, Aleksandrov A, Anokhina A, Aoki S, Ariga A, Ariga T, Bender D, Bertolin A, Bodnarchuk I, Bozza C, Brugnera R, Buonaura A, Buontempo S, Büttner B, Chernyavsky M, Chukanov A, Consiglio L, D'Ambrosio N, De Lellis G, De Serio M, Del Amo Sanchez P, Di Crescenzo A, Di Ferdinando D, Di Marco N, Dmitrievski S, Dracos M, Duchesneau D, Dusini S, Dzhatdoev T, Ebert J, Ereditato A, Fini RA, Fornari F, Fukuda T, Galati G, Garfagnini A, Goldberg J, Gornushkin Y, Grella G, Guler AM, Gustavino C, Hagner C, Hara T, Hayakawa H, Hollnagel A, Hosseini B, Ishiguro K, Jakovcic K, Jollet C, Kamiscioglu C, Kamiscioglu M, Kim JH, Kim SH, Kitagawa N, Klicek B, Kodama K, Komatsu M, Kose U, Kreslo I, Laudisio F, Lauria A, Ljubicic A, Longhin A, Loverre PF, Malgin A, Malenica M, Mandrioli G, Matsuo T, Matsushita T, Matveev V, Mauri N, Medinaceli E, Meregaglia A, Mikado S, Miyanishi M, Mizutani F, Monacelli P, Montesi MC, Morishima K, Muciaccia MT, Naganawa N, Naka T, Nakamura M, Nakano T, Nakatsuka Y, Niwa K, Ogawa S, Olchevsky A, Omura T, Ozaki K, Paoloni A, Paparella L, Park BD, Park IG, Pasqualini L, Pastore A, Patrizii L, Pessard H, Pistillo C, Podgrudkov D, Polukhina N, Pozzato M, Pupilli F, Roda M, Roganova T, Rokujo H, Rosa G, Ryazhskaya O, Sato O, Schembri A, Schmidt-Parzefall W, Shakirianova I, Shchedrina T, Sheshukov A, Shibuya H, Shiraishi T, Shoziyoev G, Simone S, Sioli M, Sirignano C, Sirri G, Sotnikov A, Spinetti M, Stanco L, Starkov N, Stellacci SM, Stipcevic M, Strolin P, Takahashi S, Tenti M, Terranova F, Tioukov V, Tufanli S, Vilain P, Vladymyrov M, Votano L, Vuilleumier JL, Wilquet G, Wonsak B, Yoon CS, Zemskova S. Discovery of τ Neutrino Appearance in the CNGS Neutrino Beam with the OPERA Experiment. PHYSICAL REVIEW LETTERS 2015; 115:121802. [PMID: 26430986 DOI: 10.1103/physrevlett.115.121802] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Indexed: 06/05/2023]
Abstract
The OPERA experiment was designed to search for ν_{μ}→ν_{τ} oscillations in appearance mode, i.e., by detecting the τ leptons produced in charged current ν_{τ} interactions. The experiment took data from 2008 to 2012 in the CERN Neutrinos to Gran Sasso beam. The observation of the ν_{μ}→ν_{τ} appearance, achieved with four candidate events in a subsample of the data, was previously reported. In this Letter, a fifth ν_{τ} candidate event, found in an enlarged data sample, is described. Together with a further reduction of the expected background, the candidate events detected so far allow us to assess the discovery of ν_{μ}→ν_{τ} oscillations in appearance mode with a significance larger than 5σ.
Collapse
|
85
|
Tanabe K, Hatanaka N, Kanazawa T, Shinozaki K, Hirabayashi N, Kanou M, Fukuda T, Matsuda H, Takashima H, Takahashi T, Hamada T, Sakimoto H, Ninomiya M. 2320 Efficacy and safety of Trastuzumab in combination with standard S-1 plus CDDP in HER-2 positive advanced gastric cancer; HOG-GC 01, a single-arm phase 2 study. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31236-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
86
|
Hashiguchi Y, Kasai M, Fukuda T, Ichimura T, Yasui T, Sumi T. 2724 Serum CEA as a tumor marker in patients with endometrial cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31491-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
87
|
Fujioka J, Doi A, Okuyama D, Morikawa D, Arima T, Okada KN, Kaneko Y, Fukuda T, Uchiyama H, Ishikawa D, Baron AQR, Kato K, Takata M, Tokura Y. Ferroelectric-like metallic state in electron doped BaTiO3. Sci Rep 2015; 5:13207. [PMID: 26289749 PMCID: PMC4542543 DOI: 10.1038/srep13207] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2015] [Accepted: 07/16/2015] [Indexed: 12/05/2022] Open
Abstract
We report that a ferroelectric-like metallic state with reduced anisotropy of polarization is created by the doping of conduction electrons into BaTiO3, on the bases of x-ray/electron diffraction and infrared spectroscopic experiments. The crystal structure is heterogeneous in nanometer-scale, as enabled by the reduced polarization anisotropy. The enhanced infrared intensity of soft phonon along with the resistivity reduction suggests the presence of unusual electron-phonon coupling, which may be responsible for the emergent ferroelectric structure compatible with metallic state.
Collapse
|
88
|
Vinks AA, Emoto C, Fukuda T. Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children. Clin Pharmacol Ther 2015; 98:298-308. [PMID: 26073179 DOI: 10.1002/cpt.169] [Citation(s) in RCA: 67] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2015] [Revised: 06/10/2015] [Accepted: 06/11/2015] [Indexed: 12/20/2022]
Abstract
During the past decades significant progress has been made in our understanding of the importance of age-appropriate development of new drug therapies in children. Importantly, several regulatory initiatives in Europe and the US have provided a framework for a rationale. In the US, most notably the enactment of the Best Pharmaceuticals for Children Act (BPCA) and Product Research and Equity Act (PREA) has facilitated the studying of on-patent and off-patent drugs in children. The biggest challenge in pediatric studies is defining a safe and effective dose or dose range in a patient population that can span from premature neonates to adolescents. From a mechanism-based perspective, advances in the science of quantitative pharmacology and pharmacometrics have resulted in the development of model-based approaches to better describe and understand important age-related factors influencing drug disposition and response in pediatric patients. The application of modeling and simulation has been shown to result in better estimates of pediatric doses as evidenced by several studies, although the optimal approach is still being debated. The extrapolation of efficacy findings from adults to the pediatric population has streamlined the development process especially for studies in older children. However, a focus on developmental changes in neonates and infants as well as further developing a paradigm for conducting pharmacodynamic studies in neonates, infants, and children remain important unmet needs. In this overview we will review current approaches for age-appropriate dose selection and highlight ongoing efforts to define exposure-response and clinical outcome relationships across the pediatric age spectrum.
Collapse
|
89
|
Fuji S, Yakushijin K, Kim SW, Yoshimura K, Kurosawa S, Fukuda T. Dynamic change of glycemic status during the early phase after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2015; 50:1473-5. [PMID: 26168070 DOI: 10.1038/bmt.2015.163] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
90
|
Origuchi T, Arima K, Umeda M, Kawashiri SY, Koga T, Ichinose K, Tamai M, Nakamura H, Miyashita T, Fujikawa K, Mizokami A, Iwanaga N, Furuyama M, Nakashima M, Aramaki T, Ueki Y, Kawabe Y, Fukuda T, Eguchi K, Kawakami A. SAT0533 Early Diagnosis is Associated with the Less Flair in Patients with Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) Syndrome. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
91
|
Koga T, Okada A, Kawakami A, Fukuda T, Hidaka T, Ishii T, Ueki Y, Kodera T, Nakashima M, Takahashi Y, Honda S, Watanabe R, Okuno H, Tamai M, Aoyagi K, Eguchi K. SAT0088 Prognostic Factors Toward Rapid Radiographic Progression in Patients with Rheumatoid Arthritis in Clinical Practice: A Japanese Multicenter, Prospective Longitudinal Cohort Study for Achieving Treat to Target Strategy. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
92
|
Ogata M, Fukuda T, Teshima T. Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: What we do and do not know. Bone Marrow Transplant 2015; 50:1030-6. [DOI: 10.1038/bmt.2015.76] [Citation(s) in RCA: 86] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2014] [Revised: 02/04/2015] [Accepted: 02/28/2015] [Indexed: 01/13/2023]
|
93
|
Shimada N, Fukuda T, Ishii Y, Sekikawa D, Ohtsuki M, Matsuda H, Kodeki K, Ohya G, Nagao F, Kimura N, Nakano S, Murakami S, Miyamoto S, Tsuchiya T. Serum hepatitis in Japan. BIBLIOTHECA HAEMATOLOGICA 2015; 23:1066-70. [PMID: 5879441 DOI: 10.1159/000384359] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
|
94
|
Hoshikawa S, Sano T, Hirato J, Oyama T, Fukuda T. Immunocytochemical analysis of p63 and 34βE12 in fine needle aspiration cytology specimens for breast lesions: a potentially useful discriminatory marker between intraductal papilloma and ductal carcinomain situ. Cytopathology 2015; 27:108-14. [DOI: 10.1111/cyt.12244] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/23/2015] [Indexed: 11/29/2022]
|
95
|
Emoto C, Fukuda T, Johnson TN, Adams DM, Vinks AA. Development of a Pediatric Physiologically Based Pharmacokinetic Model for Sirolimus: Applying Principles of Growth and Maturation in Neonates and Infants. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY 2015. [PMID: 26225230 PMCID: PMC4360665 DOI: 10.1002/psp4.17] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
This study describes the maturation of sirolimus clearance in a cohort of very young pediatric patients with vascular anomalies. The relationship between allometrically scaled in vivo clearance and age was described by the Emax model in patients aged 1 month to 2 years. Consistent with the observed increase, in vitro intrinsic clearance of sirolimus using pediatric liver microsomes showed a similar age-dependent increase. In children older than 2 years, allometrically scaled sirolimus clearance did not show further maturation. Simulated clearance estimates with a sirolimus physiologically based pharmacokinetic model that included CYP3A4/5/7 and CYP2C8 maturation profiles were in close agreement with observed in vivo clearance values. In addition, physiologically based pharmacokinetic model-simulated sirolimus pharmacokinetic profiles predicted the actual observations well. These results demonstrate the utility of a physiologically based pharmacokinetic modeling approach for the prediction of the developmental trajectory of sirolimus metabolic activity and its effects on total body clearance in neonates and infants.
Collapse
|
96
|
Yanai S, Hashiguchi Y, Kasai M, Fukuda T, Ichimura T, Yasui T, Sumi T. Early operative treatment of anti-N-methyl D-aspartate (anti-NMDA) receptor encephalitis in a patient with ovarian teratoma. CLIN EXP OBSTET GYN 2015; 42:819-821. [PMID: 26753495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
BACKGROUND Anti-N-methyl D-aspartate (anti-NMDA) receptor encephalitis is often accompanied by ovarian teratoma. Early tumor resection is reported to be effective as a treatment. CASE A 21-year-old woman presented with anti-NMDA receptor encephalitis which was accompanied by ovarian teratoma. The present case was a very rare case of an early stage of anti-NMDA receptor encephalitis receiving operative treatment before confirming the presence of anti-NMDA receptor antibody. The diagnosis was established postoperatively by identifying anti-NMDA receptor antibody. CONCLUSION In case of suspecting anti-NMDA receptor encephalitis in a patient with ovarian teratoma, early operative treatment should be considered even before confirming the presence of anti-NMDA receptor antibody.
Collapse
|
97
|
Fukuda T, Imai K, Yamauchi M, Teramae M, Hashiguchi Y, Ichimura T, Yasui T, Sumi T. Primary peritoneal cancer: study of 14 cases and comparison with epithelial ovarian cancer. EUR J GYNAECOL ONCOL 2015; 36:49-53. [PMID: 25872334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
PURPOSE OF INVESTIGATION Primary peritoneal carcinoma (PPC) is histologically similar to ovarian serous carcinoma, but its biochemical features remain obscure. The authors investigated and compared clinical findings, treatments, and outcomes of patients with PPS and those with epithelial ovarian cancer (EOC) patients. MATERIALS AND METHODS The authors retrospectively reviewed data from 14 patients with PPC and 219 patients with EOC treated at the present hospital from January 2005 to December 2012, including demographic data, pathologic findings, treatments, and outcomes. RESULTS Patients with PPC were significantly older (62.6 ± 8.4 years) than those with EOC (56.3 ± 11.3 years) (p = 0.045). There was no significant difference in serum CA-125 levels. The five-year survival rates did not differ significantly between patients with PPC (61.1%) and those with EOC (60.3%; p = 0.78); nor between patients with PPC and those with Stage III serous EOC (43.8%; p = 0.40). CONCLUSIONS Treatment strategies for EOC applied to PPC apparently led to similar survival patterns among the two patient groups. Cytoreductive surgery combined with pre/postoperative platinum-containing chemotherapy may be effective for PPC patients.
Collapse
|
98
|
Hashiguchi Y, Fukuda T, Ichimura T, Matsumoto Y, Yasui T, Sumi T, Ishiko O. Chemotherapy-induced thrombocytopenia and clinical bleeding in patients with gynecologic malignancy. EUR J GYNAECOL ONCOL 2015; 36:168-173. [PMID: 26050355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
OBJECTIVES Chemotherapy-induced thrombocytopenia seems to be a relevant problem and the risk or clinical bleeding in patients wim gynecologic malignancy is reported to be higher than other malignancy. In this study, the authors investigated chemotherapy-induced thrombocytopenia recently performed in all patients with gynecologic malignancy. MATERIALS AND METHODS Between January 2009 and December 2011, the authors examined reported chemotherapy-induced thrombocytopenia using the Common Terminology Criteria for Adverse Events (CTCAE) v.4.0. They analyzed the incidence and clinical features of chemotherapy-induced thrombocytopenia in patients with gynecologic malignancy. RESULTS During this period they administered over 1,614 infusions (29 regimens) to 291 patients. Chemotherapy-induced thrombocytopenia occurred in 43 (14.8%) patients over 56 (3.5%) chemotherapy cycles. Bleeding occurred in 13 (4.5%) patients over 14 (0.9%) cycles. Platelet transfusions were administered for eight (2.7%) patients over eight (0.5%) cycles. Median platelet count at platelet transfusions was 17,000 /μl. Chemotherapy-induced thrombocytopenia was associated with more than five previous chemotherapy cycles, previous radiotherapy, disseminated disease, distant metastatic disease, poor performance status, and taxane-including regimens. Clinical bleeding was associated with previous radiotherapy, distant metastatic disease, poor performance status, and taxane-including regimens. CONCLUSIONS Estimating bleeding risk factor such as previous radiotherapy, distant metastatic disease, poor performance status, and taxane-including regimens seem to be important for safe management of chemotherapy-induced thrombocytopenia.
Collapse
|
99
|
Gupta S, Fukuda T, Okumura Y, Stankus AP. Alzheimer's Disease Caregiver Burden in Japan and the 5 E.U. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2014; 17:A809. [PMID: 27203056 DOI: 10.1016/j.jval.2014.08.542] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|
100
|
Shiroiwa T, Shimozuma K, Fukuda T. Treatment Costs for Breast Cancer in Japan: Large Claim Database Analysis. VALUE IN HEALTH : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH 2014; 17:A735. [PMID: 27202637 DOI: 10.1016/j.jval.2014.08.104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
|